Trial Profile
Saxagliptin up-regulates nesfatin-1 secretion and inhibits erythrocyte aldose reductase activity in newly diagnosed type 2 diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Mar 2018
Price :
$35
*
At a glance
- Drugs Saxagliptin (Primary) ; Acarbose
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 15 Mar 2018 New trial record